Anaphylactoid reaction to enoxaparin in a patient with deep venous thrombosis

Pharmacotherapy

Volumn 22, Issue 11, 2002, Pages 1511-1515

  MacLaughlin, Eric J ^a   Fitzpatrick, Kevin T ^a   Sbar, Evelyn ^a   Jewell, Coty ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DALTEPARIN; DANAPAROID; ENOXAPARIN; IBUPROFEN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MULTIVITAMIN; PARACETAMOL;

ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; ARTICLE; BLEEDING; CASE REPORT; COUGHING; DEEP VEIN THROMBOSIS; DRUG EFFECT; DYSPNEA; EDEMA; ERYTHEMA; HUMAN; HYPERSENSITIVITY REACTION; MALE; PHYSICAL EXAMINATION; PRURITUS; RASH; SKIN NECROSIS; STRIDOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; URTICARIA;

ADULT; ANAPHYLAXIS; ENOXAPARIN; HUMANS; MALE; VENOUS THROMBOSIS;

EID: 0036842237     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.16.1511.33688     Document Type: Article

References (30)

1. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452-63.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-93.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and dcase-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT study. Arch Intern Med 1991;151:933-8.
4. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: A statement for healthcare professionals: Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212-45.
5. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93.
6. Aventis Pharmaceuticals. Lovenox (Enoxaparin) Package Insert. Collegeville, PA; 2001.
7. Neugut Al, Ghatak AT, Miller RL. Anaphylaxis in the United States: An investigation into its epidemiology. Arch Intern Med 2001;161:15-21.
8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
9. MacLean JA, Moscicki R, Bloch KJ. Adverse reactions to heparin. Ann Allergy 1990;65:254-9.
10. Wutschert R, Piletta P, Bounameaux H. Adverse skin reactions to low-molecular-weight heparins: Frequency, management and prevention. Drug Saf 1999;20:515-25.
11. Dux S, Pitlik S, Perry G, Rosenfeld JB. Hypersensitivity reaction to chlorbutol-preserved heparin [letter]. Lancet 1981;1:149.
12. Gaye A, Lerner C. Reactivity to preservatives in heparin [letter]. J Allergy Clin Immunol 1987;79:238.
13. Ainley EJ, Mackie IG, Macarthur D. Adverse reaction to chlorocresol-preserved heparin [letter]. Lancet 1977;1:705.
14. Odeh M, Oliven A. Urticaria and angioedema induced by low-molecular-weight heparin. Lancet 1992;340:972-3.
15. Ueda A, Nagase S, Morito N, et al. Anaphylactoid reaction induced by low-molecular-weight heparin in a hemodialysis patient. Nephron 2001;87:93-4.
16. Fried M, Kahanovich S, Dagan R. Enoxaparin-induced skin necrosis. Ann Intern Med 1996;125:521-2.
17. Sivakumaran M, Ghosh K, Munks R, Gelsthorpe K, Tan L, Wood JK. Delayed cutaneous reaction to unfractionated heparin, low molecular weight heparin and danaparoid. Br J Haematol 1994;86:893-4.
18. Tonn ME, Schaiff RA, Kollef MH. Enoxaparin-associated dermal necrosis: A consequence of cross-reactivity with heparin-mediated antibodies. Ann Pharmacother 1997;31:323-6.
19. Organon Inc. Orgaran (Danaparoid) Package Insert. West Orange, NJ; 1998.
20. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35:26-34.
21. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-7.
22. Warkentin TE. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35:17-25.
23. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001;119:95S-107.
24. Lubenow N, Greinacher A. Management of patients with heparin-induced thrombocytopenia: Focus on recombinant hirudin. J Thromb Thrombolysis 2000;10(suppl 1):47-57.
25. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: Focus on lepirudin. Circulation 2001;103:1479-84.
26. Berlex Laboratories. Refludan (Lepirudin) Package Insert. Wayne, NJ; 2001.
27. GlaxoSmithKline. Argatroban (Argatroban) Package Insert. Research Triangle Park, NC; 2002.
28. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study Circulation 1999;99:73-80.
29. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-associated thrombocytopenia study (HAT) investigators. Circulation 1999;100:587-93.
30. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.